Study of MRG007 (ARR-217) for Advanced Solid Tumors
This study is testing a new treatment called MRG007 (ARR-217) in people with advanced solid tumors, including colorectal, gastric, and pancreatic cancers. Researchers want to see how safe MRG007 is, how well your body handles it (tolerability), and if it helps shrink tumors (efficacy). Some participants will receive MRG007 alone, while others will receive MRG007 combined with Bevacizumab. To join, you must be at least 18 years old, have a life expectancy of at least 3 months, and have advanced cancer that has not responded to standard treatments or for which there are no other standard treatments. You'll also need to provide a tumor sample for CDH17 testing. The study is currently evaluating safety by looking at serious side effects and other side effects that happen during treatment.
- Study design
- This is an open-label, multi-center Phase 1 study, meaning both you and your doctors will know which treatment you are receiving. It plans to enroll 572 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Researchers will monitor for serious side effects and other side effects for up to 30 days after your last dose of study treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
At a glance
Conditions
Where it's being run
21 sites across 16 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Dose Limiting Toxicity (DLT) - Phase IaBaseline to Day 21 of the first treatment cycle
- Serious Adverse Events (SAEs)Baseline to 30 days after the last dose of study treatment
Adverse events that are fatal, life-threatening, or result in hospitalization or prolonged hospitalization, persistent or significant disability/incapacity/substantial disruption of the ability to lead a normal life, congenital anomaly/birth defect or major medical events or reactions
- Treatment-Emergent Adverse Event (TEAE)Baseline to 30 days after the last dose of study treatment
AEs that occur or worsen on or after the first dose of study treatment
- Treatment-Related Adverse EventBaseline to 30 days after the last dose of study treatment
Any reaction, side effect, or untoward event that occurs during the course of the clinical trial is considered related to the study drug.
- Objective Response Rate (ORR) as assessed by investigator - Phase IbBaseline to study completion (up to 24 months)
ORR is defined as the proportions of patients with a complete response (CR) and partial response (PR). ORR will be assessed according to RECIST v1.1.